

Novo Nordisk and Amylin - Bydureon Approval in the US - A Positive signal for the class

<https://marketpublishers.com/r/NEDE1CFD420EN.html>

Date: January 2012

Pages: 10

Price: US\$ 140.00 (Single User License)

ID: NEDE1CFD420EN

Abstracts

The approval of Bydureon in the US for the treatment of Type 2 diabetes, is important for the entire GLP-1 class and is a positive signal for the one's in the pipeline. There are about 34 GLP-1 pipeline candidates and are being designed for significant enhancement over current marketed GLP-1's. We forecast \$3billion in peak sales for the Amylin's GLP-1 franchise (Byetta, Bydureon and once monthly exenatide suspension). Bydureon is currently available in custom dosing kit, but will be soon replaced by a pen version (YE 2012/early 2013). The once monthly exenatide suspension (QM/QW) in a pen device (not require reconstitution), currently in PhIII is expected to reach the market beyond 2013, and will help Amylin further build its dominance in the GLP-1 space.

Contents

COMPANIES MENTIONED

NOVO NORDISK, AMYLIN

I would like to order

Product name: Novo Nordisk and Amylin - Bydureon Approval in the US - A Positive signal for the class

Product link: <https://marketpublishers.com/r/NEDE1CFD420EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NEDE1CFD420EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970